What is the core difference between semaglutide and tirzepatide?
Both are once-weekly injectable drugs in the incretin class, and both are FDA-approved for type 2 diabetes and for chronic weight management. The mechanistic difference is receptor count: semaglutide activates one receptor (GLP-1), while tirzepatide activates two (GIP and GLP-1).
That added GIP activity is the leading explanation for why tirzepatide tends to produce greater weight loss. GLP-1 drives appetite suppression, slowed gastric emptying, and glucose-dependent insulin release; adding GIP appears to amplify the metabolic effect. In branded terms, semaglutide is sold as Ozempic and Wegovy, and tirzepatide as Mounjaro and Zepbound.
Why does the dual mechanism matter?
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones — gut-derived signals released after eating that help regulate blood sugar and appetite. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a single molecule that activates both the GLP-1 and the GIP receptor, which is why it is described as a dual agonist or "twincretin."
GLP-1 receptor activation slows gastric emptying, increases glucose-dependent insulin secretion, suppresses glucagon, and acts on appetite centers in the brain to reduce food intake. The prevailing hypothesis for tirzepatide's larger average effect is that adding GIP receptor activity complements those GLP-1 actions on energy balance and insulin sensitivity. Importantly, the mechanism is a hypothesis for the observed difference, not a guarantee of a better outcome for any individual — the clinical endpoints from the trials, not the receptor count, are what matter for a treatment decision.
What did the head-to-head SURMOUNT-5 trial find?
Unlike most drug comparisons, these two were actually tested against each other. SURMOUNT-5 was a randomized phase 3b open-label trial in 751 adults with obesity but without diabetes that pitted tirzepatide directly against semaglutide, each titrated to its maximum tolerated dose (15 mg tirzepatide or 2.4 mg semaglutide) over 72 weeks. The result was published in the New England Journal of Medicine in 2025.
Tirzepatide was superior on the primary endpoint: a least-squares mean weight reduction of 20.2% versus 13.7% for semaglutide — a 6.5 percentage-point advantage (95% CI, −8.1 to −4.9), statistically significant at P<0.001. Tirzepatide also produced a larger waist-circumference reduction, 18.4 cm versus 13.0 cm.
The gap widens at the harder weight-loss targets. In SURMOUNT-5, the share of participants reaching each threshold was consistently higher on tirzepatide: at least 10% loss (81.6% vs 60.5%), at least 15% (64.6% vs 40.1%), at least 20% (48.4% vs 27.3%), and at least 25% (31.6% vs 16.1%). On an exploratory at-least-30% target, 19.7% of the tirzepatide group reached it versus 6.9% of the semaglutide group — making that level of loss about 2.8 times as likely with tirzepatide. This is the strongest evidence available that, on weight loss alone, the dual agonist edges out the single agonist.
How do their own pivotal obesity trials compare — and why is that weaker evidence?
Before SURMOUNT-5, the only way to compare the two for weight was to line up their separate pivotal trials. In STEP 1, semaglutide 2.4 mg produced a mean weight reduction of 14.9% at week 68 versus 2.4% on placebo. In SURMOUNT-1, tirzepatide 15 mg produced a mean reduction of about 20.9% at week 72 versus placebo. Side by side, that looks like a clear tirzepatide advantage.
But comparing across separate trials is weaker evidence than a head-to-head, because the trials enrolled different populations, ran for different durations, and had different placebo responses — differences that can flatter or penalize a drug for reasons unrelated to the molecule. That is exactly why SURMOUNT-5 matters: by randomizing the same population to one drug or the other, it removes those cross-trial confounders. The head-to-head margin (20.2% vs 13.7%) is narrower than the naive cross-trial gap, which is a useful reminder that separate-trial comparisons tend to overstate differences.
How do they compare in type 2 diabetes (SURPASS-2)?
Weight is only one axis; for type 2 diabetes the relevant head-to-head is SURPASS-2, a 40-week randomized trial that compared three tirzepatide doses (5, 10, 15 mg) against semaglutide 1 mg in adults with type 2 diabetes on metformin, published in the New England Journal of Medicine in 2021.
On the primary endpoint of glycemic control, the estimated mean reduction in HbA1c (glycated hemoglobin) was 2.01, 2.24, and 2.30 percentage points for tirzepatide 5, 10, and 15 mg respectively, versus 1.86 percentage points for semaglutide 1 mg. All three tirzepatide doses were non-inferior and superior to semaglutide 1 mg on this measure.
Body-weight reductions were also greater with tirzepatide, with a treatment difference versus semaglutide of 1.9 kg, 3.6 kg, and 5.5 kg at the 5, 10, and 15 mg doses (P<0.001 for all comparisons). One caveat for interpretation: SURPASS-2 used the 1 mg dose of semaglutide that was the approved diabetes maintenance dose at the time, not the 2.4 mg dose used for obesity — so the diabetes comparison is not run at semaglutide’s highest weight-management strength.
How do dosing and titration differ?
Both are once-weekly subcutaneous injections that start low and step up slowly to limit gastrointestinal side effects, but the brand schedules differ. For weight management, Wegovy (semaglutide) starts at 0.25 mg once weekly and titrates every 4 weeks through 0.5, 1, and 1.7 mg to a usual maintenance dose of 2.4 mg once weekly — a roughly 16-week ramp before the full dose.
Zepbound (tirzepatide) starts at 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg increments after at least 4 weeks at each step. Its approved maintenance doses for weight reduction are 5, 10, or 15 mg once weekly, with 15 mg the maximum. Because both are escalated on a per-person tolerability basis, the actual time to reach a maintenance dose varies; these schedules come straight from the FDA labels and are managed by the prescriber, not self-adjusted.
Do their approved uses differ beyond weight and diabetes?
Yes — and this is one of the clearest practical differences. Both molecules are approved for type 2 diabetes (Ozempic, Mounjaro) and for chronic weight management (Wegovy, Zepbound), but their obesity brands have each picked up a distinct extra indication.
Wegovy carries an FDA indication to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight — the indication added in 2024 on the strength of the SELECT outcomes trial. In SELECT, which enrolled 17,604 adults with cardiovascular disease and overweight or obesity but without diabetes, semaglutide 2.4 mg cut the primary composite cardiovascular endpoint to 6.5% of patients versus 8.0% on placebo (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001) over a mean 39.8 months — about a 20% relative reduction. Wegovy has since also gained an indication in noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis.
Zepbound, in turn, became in December 2024 the first drug FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA program. So the right comparison can hinge less on raw weight loss and more on which additional condition a person also has — cardiovascular risk pointing toward the semaglutide brand, sleep apnea toward the tirzepatide brand.
How do the side effects compare?
Both drugs share the incretin-class side-effect profile, which is dominated by gastrointestinal effects — nausea, diarrhea, vomiting, and constipation — that are worst during dose escalation and tend to ease over time.
The profiles differ in emphasis. Semaglutide skews toward more nausea and constipation; tirzepatide skews toward more diarrhea with somewhat less nausea. In the head-to-head SURMOUNT-5 trial, treatment was discontinued because of adverse events by 6.1% of the tirzepatide group versus 8.0% of the semaglutide group; gastrointestinal adverse events specifically led to discontinuation in 2.7% on tirzepatide versus 5.6% on semaglutide. Serious adverse events were similar between groups (4.8% vs 3.5%). Neither is a clear "gentler" option for everyone — tolerance is individual, which is why both are escalated slowly.
Which should someone choose?
On average weight loss, the head-to-head SURMOUNT-5 data favor tirzepatide, and on HbA1c in type 2 diabetes the SURPASS-2 data also favor tirzepatide over semaglutide 1 mg. But "more on average" is not the only axis, and group averages do not predict any one person's response.
Several other factors carry real weight: cost and insurance coverage (which differ by plan and change over time), the specific indication beyond weight — established cardiovascular disease points toward semaglutide's outcome data, while moderate-to-severe obstructive sleep apnea is a tirzepatide-brand indication — individual tolerability during titration, the route preferred (semaglutide also has an oral form for diabetes), and prescriber familiarity. A figure such as "20.2% versus 13.7%" describes trial-group means at a specific dose and timepoint, not a promise for an individual.
This is a clinician's call, not a self-directed one. The decision belongs in a conversation with a licensed prescriber who can weigh the individual's history, comorbidities, current medications, and goals — and who manages dose titration and monitoring over time.
Tracking either compound on PeptidePanel
Whichever a clinician prescribes, the monitoring work is identical: log doses, follow the biomarkers that matter (HbA1c, lipids, weight trend), and catch side effects early during titration. PeptidePanel is the neutral tracking layer for that — it records the protocol your clinician sets, charts your bloodwork against reference ranges, and reminds you when a dose or a lab is due.
PeptidePanel does not sell, source, supply, or prescribe any compound. It is a monitoring tool for protocols a qualified prescriber has put you on.